A clinical study on the effect of semaglutide on the immune system and other biological processes in people with Alzheimer's disease
Résumé de l'étude
This is a study aimed at evaluating the effects of semaglutide on the immune system and other biological processes in people with Alzheimer's disease. The treatment of patients with the drug semaglutide or placebo (an inactive dummy drug) is decided by chance. This study is "double-blind", meaning that neither the participants nor the study staff know the distribution between the groups.
(BASEC)
Intervention étudiée
The total duration of the study is 1 and a half years for each patient and includes 12 visits to the study center.
The study begins with a selection period to ensure that patients meet the inclusion criteria. There will then be a treatment period of 64 weeks divided into two phases: during the first 12 weeks, patients will receive either semaglutide (the tested drug) or placebo (an inactive dummy drug), which is decided at random (patients will have exactly the same chance of receiving semaglutide as placebo). In the following 52 weeks, all individuals participating in the study will receive semaglutide. The study drug must be injected into the patient by their study partner once a week under the skin using an injection pen.
The study will conclude with a 5-week observation period after the last dose of the study drug.
During the selection period, it is planned to use a brain scan (MRI) to examine the structure of the brain. During visits to the study center, there will be various examinations (e.g., height, weight, electrocardiogram, cognitive tests, questionnaires) and blood samples taken. Additionally, during two visits, there will also be a collection of cerebrospinal fluid samples.
(BASEC)
Maladie en cours d'investigation
Alzheimer's disease
(BASEC)
- Male or female, aged 55 to 75 years - Mild cognitive impairment (MCI) or mild Alzheimer's type dementia - Clinical dementia rating (Clinical Dementia Rating – CDR) with a score of 0.5 or 1 at the selection visit (visit 1). - Established amyloid positivity with either a positron emission tomography (PET) or a historical cerebrospinal fluid (CSF) sample, or a blood sample for the amyloid biomarker at selection. - Treated with acetylcholinesterase inhibitors (approved for the treatment of Alzheimer's disease) and on a stable dose for > 90 days before the selection visit (visit 1). All study participants must have a companion (study partner). (BASEC)
Critères d'exclusion
- Magnetic resonance imaging (MRI) of the brain indicating a clinically significant structural disease of the central nervous system (CNS). - MRI of the brain suggesting significant small vessel pathology. - History or evidence of autoimmune diseases such as inflammatory bowel disease, rheumatoid arthritis, lupus, glomerulonephritis, psoriasis, and any other medical condition that would require the use of systemic corticosteroids or immunosuppressants or immunostimulants in the 12 months prior to the selection visit (visit 1). - Receipt of a vaccine product (including a booster) 4 weeks before the selection visit (visit 1) or plans to receive one before visit 5. - Use of any systemic immunomodulatory drug in the 12 months prior to the selection visit or planned use of such drugs during the first 12 weeks of treatment until visit 5. (BASEC)
Lieu de l’étude
Genève
(BASEC)
Sponsor
Novo Nordisk Pharma AG
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Abteilung klinische Studien
+41 44 914 11 11
io-nwe-ch-clinical@clutternovonordisk.comNovo Nordisk Pharma AG
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale d'éthique de Genève
(BASEC)
Date d'approbation du comité d'éthique
09.10.2023
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzheimer’s disease (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible